<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01360320</url>
  </required_header>
  <id_info>
    <org_study_id>MIRACLE</org_study_id>
    <nct_id>NCT01360320</nct_id>
  </id_info>
  <brief_title>Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-</brief_title>
  <acronym>MIRACLE</acronym>
  <official_title>Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KKS Netzwerk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo controlled, multicentric trial to investigate the effect of
      diet supplementation with green tea extract containing 300mg epigallocatechin gallate (EGCG),
      the major polyphenol of green tea, on the recurrence of colon adenomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prevention of colorectal cancer is a major health care issue because of the high incidence of
      this cancer. So far, pharmaceutical chemoprevention has not gained widespread acceptance due
      to side effects of the chemopreventive agents used. Nutraceuticals such as polyphenols from
      tea plants have demonstrated remarkable therapeutic and preventive effects in molecular,
      epidemiological and clinical trials. However, controlled trials demonstrating the efficacy of
      nutraceuticals fo the prevention of colorectal cancer are largely missing.

      The investigators present this randomized, placebo controlled, multicentric trial to
      investigate the effect of diet supplementation with green tea extract containing 300mg
      epigallocatechin gallate (EGCG), the major polyphenol of green tea, on the recurrence of
      colon adenomas.

      Patients who underwent polypectomy for colonic polyps will be randomized after a one month
      verum run-in period to receive either 150mg EGCG two times daily or placebo over the course
      of three years. The beneficial safety profile of decaffeinated green tea extract, the
      quantifiable and known active content EGCG, and the accumulating evidence on its cancer
      preventive potential require in our view a validation of this compound for the
      &quot;nutriprevention&quot; of colorectal adenoma. Good accessibility and low costs might render this
      nutraceutical a top candidate for a wider use as food supplement in colon cancer prevention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of metachronous colorectal adenomas (tubulovillous, tubular, villous and serrated lesions) at the 3 year follow-up colonoscopy</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrences of colorectal adenomas or mucosal lesions</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of colorectal adenomas or mucosal lesions</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of colorectal adenomas or mucosal lesions</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Localization of colorectal adenomas or mucosal lesions</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological subtypes of colorectal adenomas or mucosal lesions</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive growth of colorectal adenomas or mucosal lesions</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of colorectal carcinoma</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translational research</measure>
    <time_frame>3 years</time_frame>
    <description>Genetic and biochemical biomarkers for recurrence of adenoma or development of dysplasia and carcinoma (blood samples and histological in tissue samples of the colorectal lesions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and feasibility</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1001</enrollment>
  <condition>Colorectal Serrated Adenomas</condition>
  <condition>Colorectal Tubular Adenomas</condition>
  <condition>Colorectal Villous Adenomas</condition>
  <condition>Colorectal Tubulovillous Adenomas</condition>
  <arm_group>
    <arm_group_label>Green tea extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG, bid for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, packed in hard gelatine capsules, bid for 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Green tea extract of Camellia Sinensis</intervention_name>
    <description>Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG
Run-in period with 150mg EGCG two times daily (p.o) for 4 weeks
150mg EGCG two times daily (p.o.) over the course of three years.
Colonoscopy after 3 years</description>
    <arm_group_label>Green tea extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Green tea extract of Camellia Sinensis followed by placebo</intervention_name>
    <description>Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG
Run-in period with 150mg EGCG two times daily (p.o.) for 4 weeks
Placebo two times daily (p.o.) over the course of three years
Colonoscopy after 3 years</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 50-80 years of age

          -  Histologically confirmed colorectal adenomas or serrated lesions removed during
             colonoscopy within the last 6 months

          -  Good performance status (ECOG &lt; 2) at study entrance

          -  Written informed consent.

        Exclusion Criteria:

          -  History of hereditary nonpolyposis colorectal cancer (HNPCC) or familial adenomatous
             polyposis (FAP)

          -  History of colon or rectal cancer, other concomitant cancers with the exemption of
             basalioma or curative treated cancers without actual anticancer medication.

          -  Intestinal malabsorption, short bowel syndrome or surgical bowel interventions leading
             to malabsorption

          -  Liver failure (hepatitis, cirrhosis, elevation of liver enzymes ALT, AST or bilirubin
             to more than 2.5 fold of the reference levels)

          -  Inflammatory bowel disease

          -  Regular intake of NSAIDs (also Cox2 inhibitors) for more than 3 months per year except
             of low-dose aspirin (100 mg per day)

          -  Immunosuppressive medication

          -  Impaired capacity to consent or who are impaired in swallowing a pill

          -  Regular consumption of green tea extract as nutritional supplement (with a content of
             EGCG of more than 100mg per day) of longer than 6 months during the past two years

          -  Allergic reactions towards green tea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Stingl, Prof.Dr.med</last_name>
    <role>Study Chair</role>
    <affiliation>Federal Institute for Drugs and Medical Devices, Bonn, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Seufferlein, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ulm, Ulm, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ostalb-Klinikum Aalen, Medizinische Klinik 1, Sekretariat Prof. Kleber</name>
      <address>
        <city>Aalen</city>
        <zip>73430</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Altenburger Land, Gastroenterologie</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg, III. Med. Klinik</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Bietigheim-Bissingen, Klinik für Innere Medizin, Gastroenterologie, Hämato-Onkologie</name>
      <address>
        <city>Bietigheim-Bissingen</city>
        <zip>74321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Buchholz, Abteilung Innere Medizin</name>
      <address>
        <city>Buchholz</city>
        <zip>21244</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln gGmbH, Krankenhaus Holweide -Medizinische Klinik-</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen, Klinik für Innere Medizin, Onkologie, Gastroenterologie</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald, Klinik und Poliklinik für Innere Medizin A</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Zeisler, Praxis für Innere Medizin und Gastroenterologie</name>
      <address>
        <city>Halle</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dres. Fechner/Behrens/Steudel - Gastroenterologisch-Onkologische Praxisklinik</name>
      <address>
        <city>Halle</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Frank-Gleich Praxis für Innere Medizin und Gastroenterologie</name>
      <address>
        <city>Halle</city>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle, Klinik für Innere Medizin I</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg, Medizinische Klinik I</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakoniekrankenhaus Mannheim, Medizinische Klinik II</name>
      <address>
        <city>Mannheim</city>
        <zip>68163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>II. Medizinische Klinik und Poliklinik der TU München, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Mühldorf Abt.Gastroenterologie</name>
      <address>
        <city>Mühldorf</city>
        <zip>84453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bogenhausen, Interdisziplinäre Onkologische Tagklinik</name>
      <address>
        <city>München</city>
        <zip>81525</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regio Kliniken Pinneberg</name>
      <address>
        <city>Pinneberg</city>
        <zip>25421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Elisabeth, I. Medizinische Klinik</name>
      <address>
        <city>Straubing</city>
        <zip>94315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik für Innere Medizin I</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Wesel, Abteilung Innere Medizin</name>
      <address>
        <city>Wesel</city>
        <zip>46485</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.gruenteestudie.de</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.krebshilfe.de</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Stingl JC, Ettrich T, Muche R, Wiedom M, Brockmöller J, Seeringer A, Seufferlein T. Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population. BMC Cancer. 2011 Aug 18;11:360. doi: 10.1186/1471-2407-11-360.</citation>
    <PMID>21851602</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 23, 2011</study_first_submitted>
  <study_first_submitted_qc>May 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Thomas Seufferlein</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Green tea</keyword>
  <keyword>polyphenol</keyword>
  <keyword>catechin</keyword>
  <keyword>EGCG</keyword>
  <keyword>Epigallocatechin gallate</keyword>
  <keyword>colorectal adenoma</keyword>
  <keyword>adenoma prevention</keyword>
  <keyword>colon cancer prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Adenoma, Villous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

